Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

In vitro-in vivo correlation of inhalable budesonide-loaded large porous particles for sustained treatment regimen of asthma.

Li J, Zheng H, Qin L, Xu EY, Yang L, Zhang L, Zhang X, Fan L, Beck-Broichsitter M, Muenster U, Chen L, Zhang Y, Mao S.

Acta Biomater. 2019 Sep 15;96:505-516. doi: 10.1016/j.actbio.2019.06.056. Epub 2019 Jun 29.

PMID:
31265921
2.

Application of a Refined Developability Classification System.

Rosenberger J, Butler J, Muenster U, Dressman J.

J Pharm Sci. 2019 Mar;108(3):1090-1100. doi: 10.1016/j.xphs.2018.10.044. Epub 2018 Oct 30.

PMID:
30389565
3.

Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material.

Vertzoni M, Kersten E, van der Mey D, Muenster U, Reppas C.

Eur J Pharm Sci. 2018 Dec 1;125:142-150. doi: 10.1016/j.ejps.2018.09.019. Epub 2018 Sep 28.

PMID:
30273661
4.

Sustained therapeutic efficacy of budesonide-loaded chitosan swellable microparticles after lung delivery: Influence of in vitro release, treatment interval and dose.

Zhang L, Yang L, Zhang X, Jiaqi L, Fan L, Beck-Broichsitter M, Zhang X, Muenster U, Wang X, Zhao J, Zhang Y, Mao S.

J Control Release. 2018 Aug 10;283:163-174. doi: 10.1016/j.jconrel.2018.05.031. Epub 2018 May 26.

PMID:
29842919
5.

Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: The impact of prandial state.

Karatza E, Goumas C, Muenster U, Reppas C, Vertzoni M.

Int J Pharm. 2017 Dec 20;534(1-2):237-241. doi: 10.1016/j.ijpharm.2017.10.015. Epub 2017 Oct 10.

PMID:
29030290
6.

Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.

Mann J, Dressman J, Rosenblatt K, Ashworth L, Muenster U, Frank K, Hutchins P, Williams J, Klumpp L, Wielockx K, Berben P, Augustijns P, Holm R, Hofmann M, Patel S, Beato S, Ojala K, Tomaszewska I, Bruel JL, Butler J.

Mol Pharm. 2017 Dec 4;14(12):4192-4201. doi: 10.1021/acs.molpharmaceut.7b00198. Epub 2017 Aug 23.

PMID:
28737403
7.

A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives.

Nguyen MA, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J, Crison J, Holm R, Li R, Mannaert E, McAllister M, Mueller-Zsigmondy M, Muenster U, Ojala K, Page S, Parr A, Rossenu S, Timmins P, Van Peer A, Vermeulen A, Langguth P.

Eur J Pharm Sci. 2017 May 1;102:1-13. doi: 10.1016/j.ejps.2017.02.029. Epub 2017 Feb 21. Review.

PMID:
28235611
8.

Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization.

Ni R, Muenster U, Zhao J, Zhang L, Becker-Pelster EM, Rosenbruch M, Mao S.

J Control Release. 2017 Mar 10;249:11-22. doi: 10.1016/j.jconrel.2017.01.023. Epub 2017 Jan 18.

PMID:
28109773
9.

Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery.

Ni R, Zhao J, Liu Q, Liang Z, Muenster U, Mao S.

Eur J Pharm Sci. 2017 Mar 1;99:137-146. doi: 10.1016/j.ejps.2016.12.013. Epub 2016 Dec 15.

PMID:
27988327
10.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
11.

The Impact of Handling and Storage of Human Fecal Material on Bacterial Activity.

Karatza E, Vertzoni M, Muenster U, Reppas C.

J Pharm Sci. 2016 Nov;105(11):3458-3461. doi: 10.1016/j.xphs.2016.07.010. Epub 2016 Aug 17.

PMID:
27544433
12.

Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.

Andreas CJ, Tomaszewska I, Muenster U, van der Mey D, Mueck W, Dressman JB.

Eur J Pharm Biopharm. 2016 Aug;105:193-202. doi: 10.1016/j.ejpb.2016.06.010. Epub 2016 Jun 15.

PMID:
27322002
13.

Interlaboratory Validation of Small-Scale Solubility and Dissolution Measurements of Poorly Water-Soluble Drugs.

Andersson SBE, Alvebratt C, Bevernage J, Bonneau D, da Costa Mathews C, Dattani R, Edueng K, He Y, Holm R, Madsen C, Müller T, Muenster U, Müllertz A, Ojala K, Rades T, Sieger P, Bergström CAS.

J Pharm Sci. 2016 Sep;105(9):2864-2872. doi: 10.1016/j.xphs.2016.03.010. Epub 2016 Apr 23.

PMID:
27112289
14.

Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.

Muenster U, Mueck W, van der Mey D, Schlemmer KH, Greschat-Schade S, Haerter M, Pelzetter C, Pruemper C, Verlage J, Göller AH, Ohm A.

Eur J Pharm Biopharm. 2016 May;102:191-201. doi: 10.1016/j.ejpb.2016.03.001. Epub 2016 Mar 5.

PMID:
26955751
15.

[Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].

Liang ZL, Wang XH, Ni R, Zhang L, Muenster U, Mao SR.

Yao Xue Xue Bao. 2015 Sep;50(9):1180-5. Chinese.

PMID:
26757557
16.

Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.

Bergström CA, Holm R, Jørgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnes J, Taylor R, Mullertz A.

Eur J Pharm Sci. 2014 Jun 16;57:173-99. doi: 10.1016/j.ejps.2013.10.015. Epub 2013 Nov 9. Review.

PMID:
24215735
17.

Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.

Lennernäs H, Aarons L, Augustijns P, Beato S, Bolger M, Box K, Brewster M, Butler J, Dressman J, Holm R, Julia Frank K, Kendall R, Langguth P, Sydor J, Lindahl A, McAllister M, Muenster U, Müllertz A, Ojala K, Pepin X, Reppas C, Rostami-Hodjegan A, Verwei M, Weitschies W, Wilson C, Karlsson C, Abrahamsson B.

Eur J Pharm Sci. 2014 Jun 16;57:292-9. doi: 10.1016/j.ejps.2013.10.012. Epub 2013 Nov 1. Review.

PMID:
24189462
18.

In vitro models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J, McAllister M, Minekus M, Muenster U, Müllertz A, Verwei M, Vertzoni M, Weitschies W, Augustijns P.

Eur J Pharm Sci. 2014 Jun 16;57:342-66. doi: 10.1016/j.ejps.2013.08.024. Epub 2013 Aug 27. Review.

PMID:
23988843
19.

In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.

Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S.

J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. doi: 10.1124/jpet.111.180240. Epub 2011 Apr 22.

PMID:
21515813
20.

Antagonism of activin by activin chimeras.

Muenster U, Korupolu R, Rastogi R, Read J, Fischer WH.

Vitam Horm. 2011;85:105-28. doi: 10.1016/B978-0-12-385961-7.00006-8. Review.

21.

Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.

Muenster U, Pelzetter C, Backensfeld T, Ohm A, Kuhlmann T, Mueller H, Lustig K, Keldenich J, Greschat S, Göller AH, Gnoth MJ.

Eur J Pharm Biopharm. 2011 Aug;78(3):522-30. doi: 10.1016/j.ejpb.2011.01.023. Epub 2011 Feb 16.

PMID:
21315152
22.

Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.

Muenster U, Grieshop B, Ickenroth K, Gnoth MJ.

Pharm Res. 2008 Oct;25(10):2320-6. doi: 10.1007/s11095-008-9632-1. Epub 2008 Jun 4.

PMID:
18523872
23.

Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.

Korupolu RV, Muenster U, Read JD, Vale W, Fischer WH.

J Biol Chem. 2008 Feb 15;283(7):3782-90. Epub 2007 Dec 3.

24.

An activin-A/C chimera exhibits activin and myostatin antagonistic properties.

Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH.

J Biol Chem. 2005 Nov 4;280(44):36626-32. Epub 2005 Aug 29.

Supplemental Content

Loading ...
Support Center